These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29627952)

  • 1. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
    Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
    Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
    Samal S; Patnaik A; Sahu F; Purkait S
    Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of H3K27me3 in meningiomas.
    Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
    Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
    Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
    Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
    Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
    Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
    Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
    J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
    Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
    Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.
    Paramasivam N; Hübschmann D; Toprak UH; Ishaque N; Neidert M; Schrimpf D; Stichel D; Reuss D; Sievers P; Reinhardt A; Wefers AK; Jones DTW; Gu Z; Werner J; Uhrig S; Wirsching HG; Schick M; Bewerunge-Hudler M; Beck K; Brehmer S; Urbschat S; Seiz-Rosenhagen M; Hänggi D; Herold-Mende C; Ketter R; Eils R; Ram Z; Pfister SM; Wick W; Weller M; Grossmann R; von Deimling A; Schlesner M; Sahm F
    Acta Neuropathol; 2019 Aug; 138(2):295-308. PubMed ID: 31069492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
    Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
    J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
    Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.